Hong Kong Consumer Finance Stock News

China Longyuan Power Group (SEHK:916) caught investor attention after reporting February 2026 power generation figures, with overall output edging up, wind output softening, and solar capacity continuing to contribute a higher share. See our latest analysis for China Longyuan Power Group. That February update comes after a strong run in the share price, with a 30 day share price return of 15.36% and a year to date share price return of 17.75% at a latest share price of HK$7.96. The 1 year...

CARsgen Therapeutics Holdings (SEHK:2171) opened FY 2025 with first half revenue of C¥51.0 million and a basic EPS loss of C¥0.14, while trailing 12 month figures show revenue of C¥84.0 million and a basic EPS loss of C¥0.95. The company reported revenue of C¥6.3 million in 1H 2024, C¥33.1 million in 2H 2024 and C¥51.0 million in 1H 2025, with basic EPS losses of C¥0.63, C¥0.81 and C¥0.14 across those respective periods. Investors are likely to focus on how margins develop from here and how...

Billion Industrial Holdings (SEHK:2299) has called a board meeting for 16 March 2026 to approve its audited 2025 final results and to consider a potential final dividend, which is a key focus for income oriented investors. See our latest analysis for Billion Industrial Holdings. The recent announcement has come after a period where the 1 year total shareholder return of 8.9% contrasts with a weaker year to date share price return of a 4.5% decline. This hints that earlier momentum has cooled...

Harbour Centre Development (SEHK:51) FY 2025 earnings snapshot Harbour Centre Development (SEHK:51) has posted its FY 2025 first half results with revenue of HK$654 million and a basic EPS loss of HK$0.28, keeping the focus squarely on how efficiently the business is converting its top line into profits. The company’s revenue increased from HK$623 million in the first half of FY 2024 to HK$654 million in the latest half. Over the same period, basic EPS moved from a loss of HK$0.01 in the...

Without a specific news headline driving attention today, WH Group (SEHK:288) still offers plenty to consider for investors who follow the global pork and packaged meats space and its recent share price performance. See our latest analysis for WH Group. At a share price of HK$9.79, WH Group has seen a 17.25% 90 day share price return, alongside a 64.32% 1 year total shareholder return and a 191.55% 3 year total shareholder return, which suggests momentum has been strong over multiple...

Tencent Holdings overview after recent share moves Tencent Holdings (SEHK:700) has attracted fresh attention after recent share price moves, with the stock last closing at HK$519. Investors are weighing this level against the group’s current earnings and business mix. See our latest analysis for Tencent Holdings. While Tencent’s 3.4% 1 day share price return has caught attention, the stock’s 30 day and year to date share price returns of 7.0% and 16.7% declines suggest momentum has cooled,...

If you are wondering whether PetroChina's recent share price leaves any value still on the table, this article will walk through what the current market price might be implying. With the stock at HK$10.40 and returns of 9.0% over 7 days, 13.5% over 30 days, 22.1% year to date, 92.1% over 1 year and 202.1% over 3 years, PetroChina has clearly been on many investors' radar. Recent coverage around PetroChina has focused on its position in the energy sector and how investors are reacting to that...

Why InSilico Medicine Cayman TopCo is on investors’ radar today InSilico Medicine Cayman TopCo (SEHK:3696) has drawn fresh attention after recent trading, with the share price at HK$55.50 and short term returns under pressure even as its year to date performance remains positive. For investors tracking AI focused biotech names, this mix of recent weakness over the past week and month alongside a stronger year to date move raises questions about how the company’s business metrics line up with...

CStone Pharmaceuticals previously announced that the UK MHRA has granted a new indication for sugemalimab monotherapy in certain adult patients with unresectable stage III non-small cell lung cancer whose disease has not progressed after platinum-based chemoradiotherapy. This adds to approvals by the European Commission and UK MHRA across multiple non-small cell lung cancer settings, potentially broadening sugemalimab’s clinical footprint in key international markets. We will now examine how...

Why RemeGen’s latest earnings matter for investors RemeGen (SEHK:9995) has just posted full year 2025 results, moving from a net loss to a net profit, with sales and earnings per share both higher than the previous year. See our latest analysis for RemeGen. That earnings turnaround appears to be reflected in the share price, with a 1-day share price return of 10.92% and a year-to-date share price return of 15.82%. The 1-year total shareholder return is also very large and suggests strong...

Innovent Biologics (SEHK:1801) is back in focus after China’s National Medical Products Administration approved a new indication for Jaypirca, its non covalent BTK inhibitor for previously treated CLL/SLL patients. See our latest analysis for Innovent Biologics. The Jaypirca update lands after a choppy few months for the stock, with a 1 day share price return of 6.18% lifting the share price to HK$83.3. The 90 day share price return shows a 9.46% decline, which contrasts with a very strong 1...

Techtronic Industries (SEHK:669) has drawn investor attention after recent share price swings, with the stock showing mixed short term moves alongside longer term gains that invite a closer look at its fundamentals. See our latest analysis for Techtronic Industries. The recent 1 day share price return of 2.0% decline and 7 day share price return of 6.7% decline sit against a 30 day share price return of 4.8% and 90 day share price return of 24.1%. At the same time, the 1 year total...

JINGDONG Industrials (SEHK:7618) has just laid out its FY 2025 scorecard, with first half revenue of CN¥10.3b and basic EPS of CN¥0.22 setting the tone for how the year is shaping up against a current share price of CN¥11.47. The company has reported revenue of CN¥8.6b and EPS of CN¥0.14 in 1H 2024, CN¥11.8b and EPS of CN¥0.23 in 2H 2024, and CN¥10.3b and EPS of CN¥0.22 in 1H 2025, while trailing twelve month figures show CN¥23.0b in revenue and EPS of CN¥1.12. With net margin over the last...

China Tobacco International (HK) (SEHK:6055) has opened FY 2025 with first half revenue of HK$10.3b and basic EPS of HK$1.02, putting fresh numbers behind a business that investors closely track for its earnings power. The company has seen reported half year revenue move from HK$8.7b in 1H 2024 to HK$10.3b in 1H 2025, while basic EPS over the same periods was HK$0.93 and HK$1.02. This result comes against a backdrop of gradually improving margins and a disciplined focus on profitability. See...

Latest Results Set the Stage for SJM Holdings’ Next Chapter SJM Holdings (SEHK:880) has posted its FY 2025 first half results with revenue of HK$14.6b and a basic EPS loss of HK$0.026, while the trailing twelve months show revenue of HK$29.6b and a basic EPS loss of HK$0.002. Over recent periods the company has seen revenue range between HK$13.8b and HK$15.0b per half year, with basic EPS moving between a loss of HK$0.023 and a profit of HK$0.023 as the business works through uneven...

Newborn Town (SEHK:9911) has drawn fresh investor attention after issuing a positive profit alert, highlighting substantial gains in revenue and profits, wider AI use across its platforms, share buybacks and inclusion in the Hang Seng Composite Index. See our latest analysis for Newborn Town. Despite the upbeat profit alert and index inclusion, Newborn Town’s 1 month share price return of a 10.59% decline and year to date share price return of a 22.49% decline suggest momentum has cooled...

JD Health International (SEHK:6618) opened FY 2025 with first half revenue of C¥35.3b and basic EPS of C¥0.82, setting the tone after a trailing twelve month period that closed with revenue of C¥73.4b and EPS of C¥1.70. The company has seen revenue step up from C¥28.3b in the first half of FY 2024 to C¥29.8b in the second half and then to C¥35.3b in the latest half, while basic EPS moved from C¥0.65 to C¥0.68 and now C¥0.82, giving investors a clearer view of how higher sales are flowing...

JD Logistics (SEHK:2618) has wrapped up FY 2025 with fourth quarter revenue of C¥63.5b, Basic EPS of C¥0.32 and net income excluding extra items of C¥2.0b, setting a clear headline for its latest earnings season update. The company has seen quarterly revenue move from C¥52.1b in Q4 2024 to C¥63.5b in Q4 2025. Trailing twelve month revenue reached C¥217.1b and net income excluding extra items came in at C¥6.6b, giving investors a fuller view of scale and consistency. With a current net profit...

Board meeting puts Giant Biogene’s 2025 results and dividend plans in focus Giant Biogene Holding (SEHK:2367) has called a board meeting for 19 March 2026 to approve its audited 2025 annual results and consider recommending a final dividend, a key calendar point for shareholders. See our latest analysis for Giant Biogene Holding. Despite a 2.49% 1 day share price return lifting the stock to HK$30.5, the 30 day share price return of 5.10% and 1 year total shareholder return of 54.97% decline...

China Resources Power Holdings (SEHK:836) has scheduled a board meeting for 18 March 2026 to approve its 2025 annual results and consider a final dividend recommendation, marking an important date for investors focused on shareholder returns. See our latest analysis for China Resources Power Holdings. Recent trading has been firm, with a 1-day share price return of 1.53% and 1-month share price return of 7.57% at HK$18.61. The 1-year total shareholder return of 8.55% and 5-year total...

China Medical System Holdings (SEHK:867) has received National Medical Products Administration approval to begin clinical trials for CMS-D008, an siRNA therapy targeting INHBE in overweight and obese individuals and using a mechanism that is different from GLP-1RAs. See our latest analysis for China Medical System Holdings. The CMS-D008 trial approval lands after a choppy stretch for the shares, with a 7 day share price return of 11.14% decline and a 30 day share price return of 10.22%...

Prada Group (SEHK:1913) has fully integrated Versace into its operations, reshaping the luxury house within the wider group structure. The group has ended the Versace Jeans Couture line as part of a broader refresh of brand positioning. New creative leadership at Versace and fresh investment in digital technology and AI tools are reshaping how the group runs its brands. MIU MIU continues to play an important role in the group, alongside the changes at Versace and ongoing digital...

Prada (SEHK:1913) has reported full year 2025 results with sales of €5,572.51 million, revenue of €5,717.52 million and net income of €851.94 million, giving investors fresh data on recent performance. See our latest analysis for Prada. The full year 2025 results land after a busy stretch for Prada, including a €300 million senior unsecured bond issue in February. The stock has seen a 9.93% 1 month share price return but a 31.53% 1 year total shareholder return decline, suggesting short term...

China's National Development and Reform Commission has announced a policy to boost intellectual property driven consumer spending. The policy aims to deepen collaborations between consumer brands and well known IPs across toys, entertainment and retail. Pop Mart International Group (SEHK:9992), a major player in branded collectibles, is directly exposed to this policy shift. The move is designed to support consumption and IP commercialization within China, with implications for both domestic...